| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
Our study demonstrated the following results: 1) Flt-4-expressing HNSCC cells possess their own VEGF-C/Flt-4 autocrine mechanism that enhances tumor cell proliferation and motility via upregulating the expression of VEGF-C itself and CNTN-1, thereby contributing to cancer progression including lymph node metastasis. 2) In pharyngeal cancer cells, selective inhibition of EP2, as well as that of Cox2, can exert anti-metastatic effects via EMT reversal (i.e., by inducing MET) that attenuates cell proliferation and migration. 3) Selective HIF-1α-inhibition may lead to anti-metastatic effects by suppressing both stemness property and EMT in pharyngeal cancer cells.
|
